Abstracts Archive - Page 674 of 2425 - ACR Meeting Abstracts

Abstract Number: 0697 • ACR Convergence 2020
Inferior Tendon Structure and Function Seen in Patients with Achilles Tendinopathy and Neovascularization of the Achilles Tendon
Brian Honick¹, Haraldur Sigurdsson¹ and Karin Silbernagel¹, ¹University of Delaware, Newark, DE
Background/Purpose: In prior research, the incidence rate of neovascularization with Achilles tendinopathy ranged between 47-88% of cases. The purpose of this study was to identify…
Abstract Number: 0696 • ACR Convergence 2020
Femoral Cartilage Ultrasound Echo-Intensity Associates with Arthroscopic Cartilage Damage in People Following Anterior Cruciate Ligament Reconstruction
Matthew Harkey¹, Erin Little², Mikaela Thompson³, Ming Zhang⁴, Jeffrey Driban⁴ and Matthew Salzler³, ¹University of Massachusetts, Worcester, MA, ²Tufts Medical Center, Cambridge, MA, ³Tufts Medical Center, Boston, ⁴Tufts Medical Center, Boston, MA
Background/Purpose: Over one-third of people will develop knee osteoarthritis within 10 years of an anterior cruciate ligament (ACL) injury. Ultrasound may be used to monitor…
Abstract Number: 0702 • ACR Convergence 2020
Distinct Murine Cartilage Microbial DNA Signatures Are Seen in High Fat Diet-Induced Obesity and Aging
Christopher Dunn¹, Cassandra Garman², Jake Martin², Vladislav Izda², Cassandra Velasco² and Matlock Jeffries², ¹University of Oklahoma Health Sciences Center, Oklahoma Cityq, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: The strongest nongenetic risk factors for primary knee OA are advanced age and obesity. We have previously shown a human cartilage microbial DNA signature…
Abstract Number: 0701 • ACR Convergence 2020
miRNome Sequencing Identifies a Unique Profile of Circulating MicroRNAs in Early Knee Osteoarthritis
S. Amanda Ali¹, Rajiv Gandhi², Pratibha Potla², Sareh Keshavarzi², Osvaldo Espin-Garcia², Konstantin Shestopaloff², Chiara Pastrello³, Dylan Bethune-Waddell², Starlee Lively², Anthony Perruccio⁴, Raj Rampersaud², Christian Veillette², Jason Rockel², Igor Jurisica², Tom Appleton⁵ and Mohit Kapoor⁶, ¹Henry Ford Health System, Detroit, MI, ²Krembil RI, Toronto, Canada, ³University Health Network, Toronto, ON, Canada, ⁴Krembil Research Institute, UHN; University of Toronto, Toronto, ON, Canada, ⁵The University of Western Ontario, LONDON, ON, Canada, ⁶Krembil RI, Toronto, ON, Canada
Background/Purpose: MicroRNAs have been shown to contribute to osteoarthritis (OA) pathophysiology, yet little is known about the circulating miRNome in OA. The circulating miRNome (e.g.…
Abstract Number: 0707 • ACR Convergence 2020
Contribution of NOTUM and Glypicans to the Development of Osteoarthritis
Arkaitz Mucientes¹, Eva Herranz¹, Pia Lois², Gloria Candelas², Lydia Abasolo¹, Luis Rodriguez-Rodriguez¹, Jose Ramon Lamas¹ and Benjamin Fernandez-Gutierrez³, ¹IdISSC, Madrid, Madrid, Spain, ²Hospital Clínico San Carlos, Madrid, Madrid, Spain, ³Hospital Clínico San Carlos / IdISSC, Madrid, Madrid, Spain
Background/Purpose: Osteoarthritis (OA) is a degenerative disease characterized by altered homeostasis of joint cartilage and bone, the functionality of which relies on chondrocytes and osteoblasts,…
Abstract Number: 0709 • ACR Convergence 2020
Anatomical Distribution of Mrgprd-expressing Nonpeptidergic C-fibers in the Mouse Knee
Alia Obeidat¹, Rachel Miller¹ and Anne-Marie Malfait¹, ¹Rush University, CHICAGO, IL
Background/Purpose: The voltage-gated sodium channel, NaV1.8, marks the majority of C-fiber nociceptors. We have used NaV1.8 tdTomato reporter mice to describe the nociceptive innervation of…
Abstract Number: 0704 • ACR Convergence 2020
The Murine Ear Wound Cartilage Superhealer Trait, Mediated by the Gut Microbiome, Is Transgenerationally Heritable Following Cecal Transplantation
Christopher Dunn¹, Cassandra Garman², Cassandra Velasco², Vladislav Izda², Jake Martin² and Matlock Jeffries², ¹University of Oklahoma Health Sciences Center, Oklahoma City, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: MRL/MpJ mice are substantially protected from developing post-traumatic osteoarthritis (OA), a trait with strong correlation to the ability to heal ear wounds. We have…
Abstract Number: 0699 • ACR Convergence 2020
Lumbar Spine Stenosis Treatment : Is Surgery Better Than Medical Treatment in Afro-Descendant Populations ?
Fabienne Louis-sidney¹, Serge Arfi¹, Moustapha Drame¹, Christophe Deligny¹, Philippe Cabre¹ and Michel de Bandt¹, ¹University Hospital Martinique, Fort de France, Martinique
Background/Purpose: Lumbar spinal stenosis (LSS) is a disabling condition, mostly prevalent in the aging population and associated with significant healthcare cost. Clinical presentation involving neurogenic…
Abstract Number: 0712 • ACR Convergence 2020
Switching from Reference to Biosimilars Does Not Reduce Efficacy and Safety in Juvenile Idiopathic Arthritis
Ilaria Maccora¹, Gabriele Simonini², Alessandra Bettiol³, Ilaria Pagnini⁴, Niccolò Lombardi⁵, Valerio Maniscalco⁶, Giada Crescioli⁵, Edoardo Marrani⁷, Roberto Bonaiuti⁵, Maria Vincenza Mastrolia⁸, Claudia Ravaldi⁹ and Alfredo Vannacci⁵, ¹Paediatric Rheumatology Unit, Anna Meyer Children's University Hospital, School of Human Health Science, Florence, Italy, Florence, Italy, ²Rheumatology Unit, Meyer Children's University Hospital, Florence; NEUROFARBA Department, University of Florence, Italy, Florence, Italy, ³2. Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Florence, Florence, Italy, Florence, ⁴1. Rheumatology Unit, Anna Meyer Children’s Hospital and Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Paediatric, University of Florence, Florence, Italy, florence, Italy, ⁵2. Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Florence, Florence, Italy., Florence, Italy, ⁶1. Rheumatology Unit, Anna Meyer Children’s Hospital and Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Paediatric, University of Florence, Florence, Italy., florence, Italy, ⁷University of Florence, Firenze, Italy, ⁸Rheumatology Unit, Meyer Children's University Hospital, Firenze, Italy, Florence, Toscana, Italy, ⁹3. Department of Health Sciences, University of Florence, Florence, Italy., Florence, Italy
Background/Purpose: Limited data about the use of biosimilar are available in children with Juvenile Idiopathic Arthritis (JIA). To evaluate the long-term efficacy and safety of switching…
Abstract Number: 0715 • ACR Convergence 2020
JIA-ACR50 Response as a Predictor of Minimal Disease Activity in Patients Aged 2–17 Years with Polyarticular-Course JIA Treated with SC Abatacept
Nicolino Ruperto¹, Hermine I Brunner², Alberto Berman³, Francisco Ávila-Zapata⁴, Gerd Horneff⁵, Maria Alessio⁶, Mara Becker⁷, Alexandre Belot⁸, Ruben Burgos-Vargas⁹, Alina Boteanu¹⁰, Claudia Goldenstein-Schainberg¹¹, Iloite Scheibel¹², Maria Teresa Terreri¹³, Lawrence Zemel¹⁴, Robert Wong¹⁵, Margarita Askelson¹⁵, Marleen Nys¹⁶, Alberto Martini¹⁷ and Daniel J Lovell², ¹Istituto Giannina Gaslini, Genova, Italy, ²PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ³Universidad Nacional de Tucumán and Centro Médico Privado de Reumatología, Tucumán, Argentina, ⁴Star Medica Hospital, Merida, Yucatan, Mexico, ⁵Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ⁶Università di Napoli Federico II, Naples, Italy, ⁷Duke University School of Medicine, Durham, NC, ⁸Centre Hospitalier Universitaire de Lyon, Lyon, France, ⁹Department of Rheumatology, General Hospital of Mexico, Ciudad de Mexico, Mexico, ¹⁰Hospital Universitario Ramón y Cajal, Madrid, Spain, ¹¹University of São Paulo, São Paulo, Brazil, ¹²Hospital Criança Conceição, Porto Alegre, Brazil, ¹³Federal University of São Paulo, São Paulo, Brazil, ¹⁴Connecticut Children’s Medical Center, Hartford, CT, ¹⁵Bristol-Myers Squibb Company, Princeton, NJ, ¹⁶Bristol-Myers Squibb Company, Braine-L’Alleud, Belgium, ¹⁷PRINTO, Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: Effectiveness of SC abatacept in patients with polyarticular-course JIA (pJIA) was shown in a 2-year, open-label Phase III international study (NCT01844518). Here we assess…
Abstract Number: 0716 • ACR Convergence 2020
Variations in Adalimumab and Etanercept Dosing in Juvenile Idiopathic Arthritis and Their Effect on Treatment Outcome: A Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry Study
Ruud Verstegen¹, Peter Shrader², Stephen Balevic³, Timothy Beukelman⁴, Colleen Correll⁵, Anne Dennos⁶, Thomas Phillips² and Brian Feldman¹, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²Duke University, Durham, ³Duke University Medical Center, Durham, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of Minnesota, Minneapolis, MN, ⁶Duke University, Durham, NC
Background/Purpose: Different dosing strategies of adalimumab and etanercept have been used over the past decade in the treatment of juvenile idiopathic arthritis (JIA). With regards…
Abstract Number: 0711 • ACR Convergence 2020
Alternative Dosing of Biologic Therapies Is Frequent Among Children with Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Colleen Correll¹, Peter Shrader², Anne Dennos³, Thomas Phillips², Natalie Shiff⁴, Ruud Verstegen⁵ and Timothy Beukelman⁶, ¹University of Minnesota, Minneapolis, MN, ²Duke University, Durham, ³Duke University, Durham, NC, ⁴Florida, Gainesville, FL, ⁵The Hospital for Sick Children, Toronto, ON, Canada, ⁶University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Biologic agents are integral to the treatment of juvenile idiopathic arthritis (JIA) and associated uveitis. Pediatric rheumatologists may increase the dosage of biologics beyond…
Abstract Number: 0719 • ACR Convergence 2020
Anti-adalimumab Antibodies Detection Using a Novel Peptide-based Assay in a Cohort of Pediatric Patients with Chronic Rheumatic Disorders: A Pilot Study
Edoardo Marrani¹, Hendrik Rusche², Francesco Terzani³, Elisa Peroni⁴, Feliciana Real-Fernandez⁵, Olivier Monasson⁴, Roberta Ponti⁶, Gabriele Simonini⁷, Anna Maria Papini³ and Paolo Rovero⁵, ¹University of Florence, Firenze, Italy, ²Peptlab@CY and Laboratory of Chemical Biology, Cergy-Paris University, Cergy-Pontoise,, France, ³PeptLab, Dep. Chemistry, University of Florence, Sesto FIorentino, Italy, ⁴Peptlab@CY and Laboratory of Chemical Biology, Cergy-Paris University, cergy-pontoise, France, ⁵PeptLab, Dep. NEUROFARBA, University of Florence, Firenze, Italy, ⁶Pediatric Department, University of Udine, udine, Italy, ⁷Rheumatology Unit, Meyer Children's University Hospital, Florence; NEUROFARBA Department, University of Florence, Italy, Florence, Italy
Background/Purpose: Immunogenicity and development of anti-drug antibodies have been associated with treatment failure and adverse events during biologic treatment. Anti-drug antibodies (ADAs) have been reported…
Abstract Number: 0714 • ACR Convergence 2020
Response to Abatacept in JIA Categories: Results from the PRCSG/PRINTO JIA Abatacept Phase IV Registry
Daniel J Lovell¹, Nikolay Tzaribachev², Esi Morgan³, Gabriele Simonini⁴, Thomas Griffin⁵, Ekaterina Alexeeva⁶, John Bohnsack⁷, Andrew Zeft⁸, Gerd Horneff⁹, Richard Vehe¹⁰, Valda Stanevicha¹¹, Stacey Tarvin¹², Maria Trachana¹³, Adam Huber¹⁴, Daniel Kietz¹⁵, Ilonka Orban¹⁶, Jason Dare¹⁷, Ivan Foeldvari¹⁸, Pierre Quartier¹⁹, Alyssa Dominique²⁰, Tzuyung Douglas Kou²⁰, Robert Wong²⁰, Alberto Martini²¹, Hermine Brunner³ and Nicolino Ruperto²², ¹PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, ³Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Anna Meyer Children's Hospital, Firenze, Italy, ⁵Levine Children's Hospital, Charlotte, NC, ⁶Scientific Center of Children’s Health of RAMS, Moscow, Russia, ⁷University of Utah and Primary Children's Hospital, Cincinnati, OH, ⁸Cleveland Clinic, Cleveland, OH, ⁹Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ¹⁰University of Minnesota, Minneapolis, MN, ¹¹Riga Stradins University, Riga, Latvia, ¹²Riley Children’s Health, Indianapolis, IN, ¹³Aristotle University of Thessaloniki, Thessaloníki, Greece, ¹⁴Dalhousie University, Halifax, NS, Canada, ¹⁵Children’s Hospital of Pittsburgh, Pittsburgh, PA, ¹⁶National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, ¹⁷University of Arkansas for Medical Sciences, Little Rock, AR, ¹⁸Hamburg Centre for Pediatric and Adolescent Rheumatology, Hamburg, Germany, ¹⁹Necker-Enfants Malades University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France, ²⁰Bristol-Myers Squibb Company, Princeton, NJ, ²¹PRINTO, Istituto Giannina Gaslini, Genova, Italy, ²²Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: Abatacept, a selective T-cell co-stimulation modulator, has been demonstrated to be well tolerated and effective in JIA in 2 Phase III studies.1,2 The ongoing…
Abstract Number: 0606 • ACR Convergence 2020
A Systematic Review Exploring Pre-COVID-19 Telehealthcare Models Used in the Management of Patients with Rheumatological Disease
Alexandra Nelson¹ and Marina Anderson², ¹University of Liverpool, Liverpool, United Kingdom, ²Lancaster University, Lancaster, United Kingdom
Background/Purpose: Recent advancements in the delivery and utilization of information and communication technologies (ICTs) have led to an increased application of telehealthcare services. Global coronavirus…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].